Ignite Creation Date:
2026-03-26 @ 3:14 PM
Ignite Modification Date:
2026-03-30 @ 9:35 PM
Study NCT ID:
NCT07489495
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-03-24
First Post:
2026-03-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2026-04-17
Start Date Type:
ESTIMATED
Primary Completion Date:
2030-11-27
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-11-27
Completion Date Type:
ESTIMATED
First Submit Date:
2026-03-20
First Submit QC Date:
None
Study First Post Date:
2026-03-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2026-03-20
Last Update Post Date:
2026-03-24
Last Update Post Date Type:
ACTUAL